Tetroxoprim

Tetroxoprim
Clinical data
ATC code	J01EE06 (WHO) (with sulfadiazine);
Identifiers
	IUPAC name 5-[3,5-Dimethoxy-4-(2-methoxyethoxy)benzyl]pyrimidine-2,4-diamine;
CAS Number	53808-87-0 ;
PubChem CID	65450;
ChemSpider	58910 ;
UNII	5R6712AY0K;
KEGG	D06097 ;
ChEMBL	ChEMBL32039 ;
CompTox Dashboard (EPA)	DTXSID80202085 ;
ECHA InfoCard	100.053.427
Chemical and physical data
Formula	C16H22N4O4
Molar mass	334.376 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCOc1c(OC)cc(Cc2cnc(N)nc2N)cc1OC;
	InChI InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20) ; Key:WSWJIZXMAUYHOE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tetroxoprim (INN) is a derivative of trimethoprim. It was first described in 1979.^[1]

Tetroxoprim is used often in combination with sulfadiazine (co-tetroxazine) for treating bacterial infections,^[2]^[3] with brand names including Biroxin and Tibirox.

References

↑ Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID 43863.
↑ Grimm H (1979). "In vitro bacteriological investigations with tetroxoprim-sulphadiazine-correlation between inhibition zone diameter and minimum inhibitory concentration". Journal of Antimicrobial Chemotherapy. 5: 37–44. doi:10.1093/jac/5.Supplement_B.37.
↑ Alkaysi H, Salem M, Gharaibeh A, Gharaibeh K, Badwan A (1992). "Bioequivalency studies on tablet formulation of tetroxoprim and sulphadiazine". Journal of Clinical Pharmacy and Therapeutics. 17: 97–99. doi:10.1111/j.1365-2710.1992.tb01274.x.

[1] Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID 43863.

[2] Grimm H (1979). "In vitro bacteriological investigations with tetroxoprim-sulphadiazine-correlation between inhibition zone diameter and minimum inhibitory concentration". Journal of Antimicrobial Chemotherapy. 5: 37–44. doi:10.1093/jac/5.Supplement_B.37.

[3] Alkaysi H, Salem M, Gharaibeh A, Gharaibeh K, Badwan A (1992). "Bioequivalency studies on tablet formulation of tetroxoprim and sulphadiazine". Journal of Clinical Pharmacy and Therapeutics. 17: 97–99. doi:10.1111/j.1365-2710.1992.tb01274.x.

[1]

[2]

[3]